Contents:

FOR EVERY MARKET, SENT QUARTERLY MARKET OUTLOOK Current market size Unique 5-Year market projections to 2012 Market outlook Comment & rating, covering 8 key areas such as use of generic drugs, intellectual property, pricing and the health systems Market structure Statistical data on imports and exports Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, funding and government policy Key national data projections FOR EVERY MARKET, SENT ANNUALLY BACKGROUND DATA Population data, including growth trends and age structure Demographic indicators detailing principal causes of death and morbidity HEALTHCARE SYSTEM Organisation & administration Health expenditure - Expenditure by source of funding and type Hospital services - Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures Outpatient care Medical personnel - Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists ACCESSING THE PHARMA MARKET Regulatory environment Distribution guide and trade fair information Domestic production CONTACT DETAILS Healthcare organisations Trade associations

Summary:

8 Markets Covered! - Indonesia - Philippines - South Korea - Thailand - Malaysia - Singapore - Taiwan - Vietnam Highlights from the report INDONESIA The Indonesian market for medical equipment and supplies was valued at US$135 million in 2007, equal to just US$0.55 per capita. In overall market terms the total is similar to Kuwait, in per capita terms the total is similar to India and Bangladesh. Indonesia spends roughly 1.2% of total health expenditure on medical devices, equal to 0.03% of total GDP. The market accounts for around 0.07% of the total world market. Only the basic medical items are produced locally and the country is reliant on imports. MALAYSIA Espicom estimates current growth in the market to be 11.1% per year. This would see the market surpass the US$1 billion mark by 2009, and reach US$1.4 billion by 2012, or US$47 per capita. Having weathered the aftermath of the 1998 economic crash better than most, market growth accelerated considerably in the following years, as imports in particular continued to increase and dominate the market. PHILIPPINES The Philippine pharmaceutical market is valued at US$1.3 billion in 2007. This is equal to around US$15 per capita, comparable with neighbouring countries such as China and Iran. Drug prices are amongst the highest in Asia, especially considering the majority of the population live below the low-income category. The use of generics is still low, despite the size and potential of the market. The government has stepped up on parallel importation and could enact changes to intellectual property laws that could in turn affect pricing. SINGAPORE Espicom estimates the Singaporean market to exhibit annual average growth of around 4%, with impressive economic indicators being tempered by the limited population size. Based on this rate, it is estimated the market will reach US$809 million by 2012, equal to US$176 per capita. The manufacture of pharmaceuticals is dominated by multinational companies and the government has indicated that it wants at least ten multinational manufacturing facilities operational in Singapore by 2010. SOUTH KOREA The Korean pharmaceutical market is the largest of all the ‘Asian Tigers’ by some considerable distance, one of the twenty largest in the world and is similar in size to that of Brazil and India. In per capita terms, the market is comparable to fellow ‘Tiger’ nations, Singapore and Taiwan. Intellectual property protection, long regarded as being insufficient, is likely to improve with the Free Trade Agreement (FTA) signed with the US in 2007, with an improved patent linkage system to be implemented by 2009. TAIWAN Taiwan is a difficult, but attractive market with strong fundamentals. Taiwan’s healthy economy, steadying currency and growing imports of pharmaceuticals should see the pharma market surpass the US$6 billion mark by 2012. There is a heavy multinational presence - over 70% of the market is controlled by overseas multinationals. Over 100 generic drug manufacturers currently operate in Taiwan. An opaque regulatory process and discriminatory reimbursement practices exist and legislation to bring the country more in line with international standards has been announced, but so far, little has changed. THAILAND Espicom estimates real market growth to be around 7.7% per year, with the total likely to reach US$663 million by 2012. Per capita spending is estimated to be around US$10 by 2012, the fourth lowest of the Asian Tigers. This figure may be revised downwards depending on the country’s political situation following the military coup in September 2006. The economic downturn some years ago hit imports hard allowing the sizeable domestic production sector to grow. VIETNAM The pharmaceutical market is expected to expand slowly in Vietnam over the next few years. The government hopes to boost per capita spending to US$10-15 by 2010, through a major development programme, although this figure looks ambitious. Opportunities exist within the Vietnamese market in terms of specialist pharmaceutical production. The country’s accession into the WTO in January 2007 is expected to further open up the market and make it more attractive to investors.

Countries Covered

- Indonesia - Philippines - South Korea - Thailand - Malaysia - Singapore - Taiwan - Vietnam